In a significant strategic evolution within the business-to-business (B2B) media landscape, Cleveland-based WTWH Media—the parent organization behind Drug Discovery & Development—officially announced its transformation into Arrowfly on July 13, 2026. This rebranding marks a pivot point for the company as it seeks to unify its expansive portfolio of over 40 media brands and 45 industry events under a singular, modernized corporate identity.
While the corporate entity has adopted the name Arrowfly, the editorial integrity and operational structure of its flagship publications remain unchanged. Drug Discovery & Development will continue to operate under its established brand, maintaining its dedicated editorial staff, archives, newsletters, and digital presence. This continuity is a core component of the transition, designed to reassure stakeholders that the move is one of growth and unification rather than operational disruption.
The Strategic Logic Behind the Rebrand
The transition from WTWH Media to Arrowfly is not merely a cosmetic change; it reflects the maturation of a company that has undergone aggressive scaling over the past several years. Founded on the principles of high-level B2B engagement, the company has carved out a niche by serving as a bridge between technical expertise and commercial application across three primary pillars: engineering, healthcare and life sciences, and the food, retail, and hospitality sectors.
For industry professionals, the change signals a commitment to a more cohesive brand ecosystem. Arrowfly operates at the intersection of complex, high-stakes industries where "editorial authority" is the primary currency. By consolidating its identity, the company aims to better leverage its cross-network resources, providing more robust data, deeper market intelligence, and more effective networking opportunities for its diverse audience.
Chronology of Evolution: From WTWH to Arrowfly
The journey toward the formation of Arrowfly has been defined by a series of strategic milestones that have transformed the company from a niche media provider into a comprehensive B2B powerhouse.
The Foundation and Early Growth
The entity originally known as WTWH Media established its reputation by focusing on technical engineering and design communities. By fostering deep relationships with engineers and product developers, the company developed a template for success: creating content that is highly technical, authoritative, and indispensable to the professionals who consume it.
The 2022 Inflection Point
The trajectory of the company shifted significantly in 2022 with the establishment of a strategic partnership with Mountaingate Capital. This infusion of capital and expertise provided the necessary leverage to expand the company’s footprint, particularly within the healthcare and life sciences sectors. Following this partnership, the company embarked on an acquisition spree, bringing various industry-leading publications and event brands into its fold.
The Leadership Transition (2025)
In 2025, the company appointed Matt Logan as CEO. A veteran of the B2B media sector with over 25 years of experience, Logan was tasked with navigating the complexities of integrating the company’s disparate brands into a unified front. Under his stewardship, the company moved toward the rebranding initiative that culminated in the launch of Arrowfly this July.
Supporting Data: The Scale of the Arrowfly Ecosystem
To understand the scope of the Arrowfly brand, one must look at the breadth of the infrastructure the company manages. Currently, the Arrowfly network comprises:
- Diverse Portfolio: Over 40 B2B media brands serving niche markets.
- Event Infrastructure: 45+ industry events designed to connect buyers and sellers in high-barrier-to-entry sectors.
- Sector Networks:
- Engineering: Focused on robotics, design, and manufacturing.
- Healthcare & Life Sciences: Including Drug Discovery & Development, medical device sector news, health systems, senior care, and behavioral health.
- Food, Retail, & Hospitality: Focused on the logistics and management of consumer-facing industries.
Drug Discovery & Development continues to serve as a critical component of the healthcare and life sciences network. By operating alongside other brands that cover the medical device sector and health systems, the publication benefits from a synergistic flow of data and cross-industry intelligence that is rare in specialized B2B media.
Official Responses and Corporate Vision
In his statement regarding the launch, CEO Matt Logan emphasized that the rebranding is an extension of the company’s original mission, rather than a departure from it.
"We built this company by earning the trust of professionals in industries where editorial authority matters," Logan stated. "The name is new, but the foundation is the same: editors who speak each industry’s language, events that connect buyers and sellers who would never meet otherwise, and communities that professionals rely on for the insight and intelligence they need to make real decisions."
The leadership team at Arrowfly is positioning the brand as a facilitator of "real decisions." In an era of information overload, the company claims that its value proposition lies in the ability to filter the noise and provide actionable, verified data. This is particularly relevant in the drug discovery pipeline, where the cost of a poor decision—based on inaccurate or outdated information—can reach billions of dollars.
Implications for the Industry
The rebranding of a major B2B media player like Arrowfly has several implications for the pharmaceutical, biotech, and medical research communities.
1. Unified Intelligence
As the industry moves toward more integrated healthcare ecosystems, Arrowfly’s ability to draw on its broader network—ranging from medical device engineering to behavioral health—allows for a more holistic view of the life sciences landscape. Readers of Drug Discovery & Development can expect to see more interdisciplinary content that reflects how these sectors are increasingly converging.
2. Enhanced Networking Opportunities
The "Arrowfly" identity suggests a more seamless integration of the company’s 45+ events. For professionals in the drug discovery space, this means potentially easier access to cross-industry conferences and summits where they can connect with vendors and partners from adjacent industries, such as advanced manufacturing or medical device engineering, which are vital to the future of drug delivery and diagnostics.
3. Continued Commitment to Editorial Rigor
The decision to keep the editorial staff and publication names intact serves as a signal to the market that the rebranding will not dilute the intellectual quality of the content. In the pharmaceutical industry, where precision is paramount, this continuity is essential. Editorial teams, led by industry experts like Brian Buntz—who has spent 18 years covering life sciences, clinical trials, and medical technology—are expected to maintain the high standards that the audience has come to rely on.
Looking Ahead: The Future of Arrowfly
As Arrowfly moves forward, the industry will be watching to see how the company utilizes its new, unified brand to integrate AI-driven data analysis into its offerings. With a growing focus on tools ranging from Natural Language Processing (NLP) and clustering to predictive analytics, the company is positioning itself to be more than just a media outlet; it is evolving into a data-intelligence partner.
For the readers of Drug Discovery & Development, the transition to Arrowfly represents the start of a more connected, data-rich experience. While the URL and the familiar faces of the editorial team remain, the corporate backing provided by Arrowfly promises a future of expanded resources and a deeper commitment to the professionals driving innovation in the lab and beyond.
For more information on the company’s future initiatives and to explore its complete portfolio of brands, readers can visit the newly established corporate hub at arrowfly.com.
About the Editorial Direction:
The editorial mission of Drug Discovery & Development remains steadfast under the Arrowfly umbrella. With over two decades of expertise in the life sciences media sector, our team continues to explore the intersection of clinical research, regulatory compliance, and cutting-edge drug discovery technology. By focusing on data-driven journalism and expert analysis, we aim to provide the insights necessary to navigate the rapidly shifting landscape of modern pharmacology.
About the Author
